current
strategi
antivir
therapeut
target
viru
specif
directli
altern
approach
drug
discoveri
might
enhanc
immun
respons
broad
rang
virus
base
clinic
observ
human
success
genet
strategi
experiment
model
reason
improv
interferon
ifn
signal
system
might
better
protect
viral
infect
aim
identifi
small
molecular
weight
compound
might
mimic
benefici
effect
improv
antivir
defens
accordingli
develop
cellbas
highthroughput
screen
ht
assay
identifi
small
molecul
enhanc
ifn
signal
pathway
compon
assay
base
phenotyp
screen
increas
ifnstimul
respons
element
isr
activ
fulli
autom
robust
format
applic
assay
system
librari
compound
includ
alreadi
approv
approv
drug
led
identif
compound
signific
isr
activ
chose
anthracyclin
antibiot
idarubicin
valid
mechan
base
activ
submm
rang
found
idarubicin
action
increas
isr
activ
manifest
member
drug
class
independ
cytotox
topoisomeras
inhibitori
effect
well
endogen
ifn
signal
product
also
observ
compound
confer
consequ
increas
ifnstimul
gene
isg
express
signific
antivir
effect
use
similar
doserang
cellcultur
system
inocul
encephalomyocard
viru
emcv
antivir
effect
also
found
compound
concentr
one
observ
cytotox
taken
togeth
result
provid
proof
concept
use
activ
compon
ifn
signal
pathway
improv
ifn
efficaci
antivir
immun
defens
well
valid
ht
approach
identifi
small
molecul
might
achiev
therapeut
benefit
signific
progress
develop
vaccin
therapeut
virus
still
major
gap
medic
therapi
common
type
viral
infect
type
infect
vaccin
still
ineffect
due
new
emerg
strain
exhibit
signific
offtarget
effect
similarli
efficaci
antivir
therapeut
often
limit
pathogen
resist
anoth
sign
difficulti
keep
rapidli
evolv
viral
genom
altern
agent
specif
directli
target
viru
possibl
improv
natur
host
defens
broad
rang
virus
although
antivir
defens
exhibit
signific
complex
redund
one
system
stand
use
target
improv
one
base
action
interferon
ifn
within
ifn
system
similarli
complex
transcript
factor
remark
central
compon
critic
function
activ
type
ifn
figur
consequ
genet
loss
function
caus
mark
suscept
viral
infect
mice
human
moreov
modif
form
improv
effici
ifn
signal
transduct
result
improv
control
viral
infect
observ
indic
ifnsign
pathway
subject
socal
rheostat
adjust
wherein
downregul
caus
increas
suscept
viral
infect
wherea
upregul
might
lead
increas
effici
ifnstimul
gene
isg
express
control
infect
present
studi
aim
mimic
benefici
action
modif
small
molecul
also
enhanc
activ
ifn
signal
pathway
describ
develop
highthroughput
screen
ht
system
novel
small
molecular
weight
compound
socal
small
molecul
might
increas
isg
express
antivir
activ
develop
screen
system
gener
cell
line
stabli
express
human
interferonstimul
respons
element
isr
drive
luciferas
report
gene
isr
gene
promot
element
respons
type
ifn
signal
mediat
host
defens
wide
rang
virus
establish
isrereport
cell
line
respond
linearli
ifnb
concentr
treatment
time
convert
assay
autom
format
screen
alreadi
approv
approv
drug
also
screen
librari
phosphatas
inhibitor
might
mediat
increas
phosphorylationactiv
analysi
identifi
seri
divers
compound
capabl
significantli
increas
isr
activ
one
compound
particular
anthracyclin
antibiot
idarubicin
hydrochlorid
use
explor
mechan
action
valid
propos
small
molecul
enhanc
isr
activ
drive
higher
level
isg
express
improv
control
viral
level
find
provid
concept
current
antivir
therapeut
act
directli
specif
viral
protein
wherea
nextgener
antivir
might
act
enhanc
host
immun
broad
rang
virus
either
alon
togeth
approach
might
better
address
current
need
effect
treatment
common
well
new
emerg
viral
infect
base
observ
cell
show
increas
activ
endogen
isr
promot
element
establish
cell
line
stabli
express
isrecontain
gene
promot
drive
click
beetl
luciferas
report
gene
figur
use
cell
parent
line
cell
well
cell
express
endogen
clonal
line
show
ifnbinduc
isrepromot
driven
luciferas
activ
design
cell
initi
assay
develop
use
cell
establish
optim
luciferas
light
reaction
time
celllin
base
luminesc
signal
stabil
time
cours
reaction
optim
readout
window
min
start
reaction
chosen
subsequ
experi
figur
optim
cell
growth
time
respons
variou
ifnb
treatment
time
concentr
test
cell
line
cell
line
exhibit
distinct
ifnb
treatment
time
maxim
signal
h
cell
h
cell
although
lower
signal
magnitud
obtain
cell
compar
cell
cell
show
specif
ifnb
compar
ifnc
treatment
ifnb
treatment
time
period
test
figur
rang
ifnb
ifnc
concentr
figur
g
thu
cell
chosen
assay
develop
achiev
assay
autom
miniatur
isr
activ
assay
first
autom
plate
reformat
plate
format
assay
exhibit
nearmaxim
signal
cell
per
well
consist
welltowel
platetopl
reproduc
figur
format
signal
background
sb
ratio
coeffici
varianc
achiev
excel
perform
comparison
publish
standard
repres
result
cell
treat
ifnb
uml
h
compar
dmso
vehicl
alon
provid
tabl
result
indic
develop
quantit
specif
cellbas
ht
assay
ifnrespons
gene
promot
activ
use
autom
isreact
assay
perform
screen
chemic
compound
librari
librari
consist
compound
john
hopkin
clinic
compound
librari
jhccl
fda
approv
approv
drug
addit
includ
compound
screenwel
phosphatas
inhibitor
librari
base
observ
improv
ifn
signal
cell
correl
prolong
phosphoryl
compound
test
differ
concentr
mm
simultan
treatment
ifnb
uml
concentr
initi
inflexion
ifn
concentrationrespons
curv
shown
figur
treatment
condit
duplic
second
plate
assay
plate
also
contain
control
well
contain
rang
ifn
figur
scheme
ifn
signal
transduct
type
ifn
signal
start
activ
ifnab
receptor
ifnar
subsequ
activ
consequ
recruit
phosphoryl
enabl
reruit
releas
phosphoryl
heterodim
bound
complex
bind
ifn
stimul
respons
element
isr
concert
recruit
transcript
coactiv
drive
ifnstimul
gene
isg
transcript
b
concentr
uml
quadrupl
figur
arrang
achiev
excel
signal
reproduc
duplic
compound
plate
well
signal
consist
full
screen
run
assay
plate
duplic
pair
figur
c
raw
data
normal
scale
zscore
summar
found
data
point
total
data
point
repres
compound
test
concentr
isr
activ
zscore
figur
data
set
repres
individu
compound
compound
isr
activ
zscore
one
dose
compound
hit
compound
total
compound
librari
select
valid
base
combin
doserespons
characterist
interrepl
reproduc
approach
captur
compound
highest
zscore
support
repurpos
drug
discoveri
strategi
screen
hit
found
broad
rang
drug
class
figur
primari
hit
subject
primari
valid
isr
activ
broader
rang
concentr
drug
ifnb
uml
among
primari
confirm
screen
hit
idarubicin
hydrochlorid
rank
highest
potenc
enhanc
isr
activ
ie
idarubicin
exhibit
signific
effect
lower
concentr
compound
isr
valid
found
idarubicin
caus
concentrationdepend
increas
isr
activ
rang
ifnb
treatment
concentr
highli
signific
effect
low
nm
idarubicin
combin
uml
ifnb
figur
structur
idarubicin
show
characterist
featur
anthracyclin
antibiot
unrel
antivir
compound
clinic
use
valid
effect
idarubicin
isr
activ
test
three
anthracyclin
daunorubicin
doxorubicin
epirubicin
similar
chemic
structur
idarubicin
compound
also
show
capac
significantli
increas
isr
activ
figur
addit
found
immun
activ
dmxaa
vadimezan
imiquimod
caus
increas
isr
activ
concentr
rang
figur
compound
appear
directli
activ
immun
cell
includ
increas
ifn
product
howev
present
work
specif
studi
nonhematopoiet
cell
sinc
popul
appear
critic
defens
least
type
virus
also
found
cytotox
effect
idarubicin
consist
previou
observ
present
condit
major
effect
idarubicin
cell
viabil
detect
drug
concentr
mm
isreactiv
effect
idarubicin
occur
concentr
caus
major
effect
cell
viabil
figur
nonetheless
idarubicin
best
known
antineoplast
agent
act
via
dna
intercal
topoisomeras
ii
inhibit
determin
whether
effect
idarubicin
isr
activ
relat
topoisomeras
ii
inhibit
test
three
potent
topoisomeras
inhibitor
etoposid
concentr
known
caus
topoisomeras
ii
inhibit
contrast
idarubicin
compound
caus
signific
increas
isr
activ
figur
fact
two
topoisomeras
inhibitor
etoposid
caus
decreas
isr
activ
concert
cytotox
effect
higher
concentr
find
indic
capac
idarubicin
activ
isr
compon
ifn
signal
pathway
occur
independ
topoisomeras
inhibit
togeth
find
provid
evid
idarubicin
capac
increas
isr
activ
independ
antineoplast
properti
drug
also
observ
effect
idarubin
anthracyclin
isr
activ
occur
lower
concentr
drug
ifnb
coadminist
particularli
highest
concentr
ifnb
uml
figur
exampl
ec
idarubicin
decreas
concentr
ifnb
increas
tabl
find
suggest
idarubicin
might
somehow
interact
ifn
signal
pathway
regard
also
found
effect
idarubicin
isr
activ
observ
baselin
condit
detect
product
endogen
ifnb
administr
exogen
ifnb
data
shown
figur
result
suggest
effect
idarubicin
isr
activ
independ
ifn
product
action
inde
also
found
effect
idarubicin
isr
activ
persist
without
chang
effect
ifnab
receptor
blockad
figur
togeth
find
indic
idarubicin
caus
increas
isr
activ
independ
ifn
product
ifnifnreceptor
interact
instead
act
downstream
ligandreceptor
bind
ifn
signal
pathway
subject
idarubicin
valid
isr
activ
assay
isg
express
antivir
activ
isg
express
cell
treat
rang
concentr
idarubicin
ifnb
harvest
gene
express
use
quantit
realtim
pcr
assay
found
idarubicin
increas
express
antivir
gene
synthetas
particularli
ifnb
treatment
figur
effect
drug
isg
express
cell
indic
drug
specif
gene
express
found
similar
result
antivir
isg
guanylatebind
protein
three
isg
figur
data
shown
antivir
activ
cell
treat
idarubicin
along
without
ifnb
assess
control
encephalomyocard
viru
emcv
level
virusinduc
cytopath
effect
select
emcv
sinc
previous
found
sensit
improv
ifn
signal
present
experi
found
idarubicin
treatment
rel
low
concentr
nm
caus
signific
decreas
emcv
titer
baselin
ifnb
treatment
rel
low
concentr
uml
figur
addit
observ
idarubicindepend
improv
viral
control
translat
signific
decreas
viral
cytopath
effect
treatment
condit
figur
higher
concentr
idarubicin
combin
ifnb
treatment
caus
signific
cytotox
effect
data
shown
consist
antineoplast
properti
drug
nonetheless
result
rel
low
concentr
idarubicin
provid
proofofconcept
small
molecul
activ
isr
compon
ifn
signal
pathway
allow
increas
isg
express
improv
control
viral
level
present
studi
undertaken
discov
antivir
therapeut
broadli
increas
host
defens
focus
ifn
system
central
antivir
respons
although
recogn
lab
pursu
target
limit
success
past
previou
investig
use
administr
ifn
increas
antivir
respons
therapeut
goal
other
side
effect
ifn
administr
proven
ratelimit
similarli
investig
attempt
boost
ifn
product
eg
administr
tolllik
receptor
tlr
agonist
cpg
imiquimod
agent
also
caus
similar
side
effect
small
molecul
dmxaa
activ
multipl
immun
pathway
nfkb
nod
map
kinas
ineffect
antivir
unless
administ
infect
circumv
least
issu
ifn
product
toxic
specif
therefor
pursu
goal
antivir
drug
discoveri
novel
screen
approach
identifi
small
molecul
enhanc
might
select
boost
activ
effici
ifn
signal
pathway
specif
approach
base
previou
success
use
modifi
signal
pathway
work
demonstr
design
form
design
base
doublecystein
substitut
abl
enhanc
ifn
signal
better
control
viral
replic
although
gene
express
would
challeng
translat
practic
applic
mechan
action
serv
guid
design
screen
strategi
identifi
small
molecul
could
mimic
antivir
benefit
regard
also
recogn
phenotyp
screen
approach
proven
effect
targetbas
approach
discoveri
firstinclass
small
molecul
drug
thu
targetbas
approach
defin
direct
drug
action
particular
target
allow
analysi
refin
structur
function
also
wast
resourc
molecular
hypothes
use
design
screen
assay
may
relev
diseas
meanwhil
phenotyp
screen
take
longer
term
hittolead
develop
provid
protein
pathway
target
requir
prior
knowledg
molecular
mechan
action
importantli
activ
found
phenotypicbas
approach
often
effect
translat
therapeut
impact
diseas
model
present
work
take
advantag
strategi
extent
devis
screen
incorpor
molecular
mechan
ie
enhanc
specif
type
ifn
signal
pathway
need
achiev
phenotyp
ie
identifi
compound
could
increas
type
signal
pathway
regardless
specif
mechan
consid
factor
observ
model
system
design
cellbas
luciferas
report
assay
measur
type
idepend
isr
activ
assay
prove
yield
excel
signaltobackground
z
factor
specif
ifnb
treatment
ifnc
treatment
suitabl
autom
screen
furthermor
construct
design
use
click
beetl
green
luciferas
assay
pair
luciferas
report
gene
develop
dual
color
assay
report
activ
signal
pathway
includ
type
ii
ifnc
activ
sequenc
ga
promot
activ
mediat
defens
intracellular
bacteria
relat
approach
use
screen
small
molecul
increas
ga
activ
antiprolif
proapoptot
effect
cancer
cell
other
screen
compound
inhibit
type
ifn
product
signal
isrerfp
report
system
also
use
screen
assess
effect
immunostimulatori
rna
other
use
less
direct
approach
screen
compound
might
use
mechan
decreas
viral
level
howev
knowledg
present
studi
conduct
first
semiquantit
screen
measur
isr
activ
discov
small
molecul
enhanc
type
ifn
signal
pathway
broadspectrum
antivir
therapeut
primari
screen
identifi
idarubicin
basi
capac
significantli
increas
isr
activ
subsequ
valid
assay
demonstr
idarubicin
facilit
isg
express
control
viral
replic
cytopath
effect
other
previous
report
antivir
properti
anthracyclin
time
ago
mechan
antivir
action
elucid
present
studi
observ
druginduc
cytotox
doserang
similar
report
previous
howev
establish
effect
idarubicin
antivir
ifn
pathway
independ
cytotox
topoisomeras
inhibit
idarubicin
enhanc
ifn
signal
pathway
output
question
whether
drug
might
also
caus
ifndriven
cell
death
howev
found
increas
cytotox
cell
treat
idarubicin
ifn
togeth
compar
cell
treat
idarubicin
alon
also
found
idarubicin
concentr
activ
isr
compon
ifn
signal
pathway
significantli
less
requir
major
cytotox
thu
conclud
idarubicin
effect
ifn
signal
distinct
effect
dnabas
cytotox
dose
depend
effect
underlin
need
conduct
screen
multipl
concentr
test
compound
particularli
lower
concentr
prevent
fals
neg
hit
due
cytotox
effect
analysi
drug
mechan
studi
demonstr
antivir
activ
idarubicin
close
relat
anthracyclin
deriv
enhanc
activ
type
ifn
signal
pathway
data
show
enhanc
effect
idarubicin
base
isr
activ
isg
express
independ
ifn
product
ifnifnreceptor
interact
sinc
effect
idarubicin
unchang
ifnreceptor
blockad
find
suggest
idarubicin
activ
isr
due
action
ifn
signal
pathway
distal
ligandreceptor
bind
eg
level
receptorassoci
jak
kinas
downstream
format
transport
bind
andor
assembl
isr
transcript
complex
regard
anthracyclin
known
inhibit
dna
rna
synthesi
intercal
base
pair
dnarna
strand
prevent
replic
whether
mechan
affect
isr
gene
promot
element
still
need
defin
present
screen
approach
overcom
uncertainti
molecular
mechan
use
phenotyp
rather
targetbas
screen
approach
therebi
captur
compound
increas
activ
ifn
signal
pathway
either
establish
undefin
mechan
sum
describ
valid
phenotyp
screen
strategi
identifi
small
molecul
enhanc
activ
type
ifn
signal
pathway
consequ
improv
antivir
host
defens
approach
design
lead
discoveri
drug
activ
broad
rang
virus
clinic
applic
well
experiment
tool
compound
understand
ifndepend
immun
mechan
current
approach
defin
basi
ifn
signal
transduct
particularli
vivo
often
reli
complex
transgen
gene
target
approach
thu
use
small
molecul
enhanc
sme
ifn
signal
pathway
may
provid
much
greater
flexibl
eas
applic
achiev
transient
adjust
ifnrel
action
consequ
scientif
clinic
benefit
approach
therebi
prove
use
discov
drug
activ
broad
rang
virus
well
effect
condit
eg
multipl
sclerosi
melanoma
efficaci
ifn
treatment
might
benefit
enhanc
ifn
signal
pathway
stimul
agent
chemic
compound
ifnb
ifnc
obtain
pbl
interferon
sourc
piscataway
nj
dilut
aliquot
accord
manufactur
recommend
store
john
hopkin
clinic
compound
librari
jhccl
obtain
dr
david
sullivan
john
hopkin
univers
screenwel
phosphatas
inhibitor
librari
obtain
enzo
life
scienc
farmingdal
ny
chemic
compound
obtain
sigma
aldrich
st
loui
mo
construct
vector
first
gener
isr
sequenc
tataa
box
pucminusmc
vector
blue
heron
biotechnolog
bothel
wa
clone
sequenc
chromaluc
report
vector
promega
madison
wi
ligat
site
use
dna
ligas
life
technolog
carlsbad
ca
dna
sequenc
result
vector
confirm
carri
bigdy
termin
sequenc
reaction
life
technolog
abi
capillari
sequenc
vector
ppur
select
vector
clontech
mountain
view
ca
cotransfect
ratio
cell
increas
likelihood
cell
toler
puromycin
select
mgml
contain
one
copi
addit
ppur
cell
obtain
g
stark
cleveland
clinic
cell
obtain
brett
washington
univers
transfect
perform
use
transfect
reagent
roch
appli
scienc
indianapoli
limit
dilut
use
obtain
individu
cell
clone
screen
luciferasemedi
luminesc
treatment
ifnb
uml
biotek
synergi
multimod
plate
reader
biotek
winooski
vt
clonal
cell
exhibit
stabl
express
use
assay
develop
optim
luciferas
light
reaction
test
seri
flash
glow
luminesc
substrat
system
lyse
live
cell
includ
dluciferin
fisher
scientif
pittsburgh
pa
chromaglo
luciferas
assay
system
promega
steadylit
plu
report
gene
assay
system
perkin
elmer
waltham
rang
incub
condit
steadylit
plu
system
select
base
kinet
profil
effect
ifnb
concentr
treatment
time
assess
variabl
constant
assay
autom
format
custom
fulli
integr
robot
system
system
equip
includ
calip
sciclon
alh
workstat
perkin
elmer
washer
biotek
liquid
handl
autom
licon
incub
thermo
scientif
cold
storag
plate
autom
cytomat
incub
thermo
scientif
cell
cultur
environ
separ
hotel
storag
plate
room
temperatur
synergi
plate
reader
flexis
plate
heat
sealer
k
bioscienc
beverli
calip
twister
ii
beckman
sagian
orca
robot
arm
linear
rail
beckman
coulter
fullerton
ca
construct
allow
transfer
plate
reagent
plasticwar
instrument
need
manual
interfer
screen
assay
entir
system
enclos
custommad
laminar
flow
hood
allow
ht
screen
capabl
steril
condit
system
demonstr
satisfactori
perform
format
assay
miniatur
format
retest
reproduc
stabil
ifnb
vehicl
dmso
treatment
condit
achiev
simultan
treatment
cell
ifnb
variou
compound
concentr
avoid
reagent
degrad
time
screen
run
modular
manner
precis
timelin
figur
first
step
includ
product
plate
appropri
concentr
compound
ifnb
storag
separ
plate
made
four
compound
concentr
mm
twister
ii
sciclon
orca
licon
cold
storag
incub
handl
step
second
step
cell
plate
cell
per
well
assay
plate
n
step
accomplish
seven
batch
assay
plate
per
batch
use
sciclon
uniform
suspens
cell
maintain
intermitt
mix
sciclon
deck
cell
plate
simultan
compound
stock
plate
seal
use
flexis
stack
back
twister
ii
rack
storag
third
step
cell
allow
grow
h
treat
compound
ifn
solut
step
requir
plate
contain
cell
brought
cytomat
incub
sciclon
deck
concert
set
compoundifn
dilut
plate
cold
storag
incub
cell
treatment
time
assay
plate
would
incub
h
final
step
perform
luciferas
assay
last
step
robot
program
assay
plate
develop
luciferas
light
reaction
min
plate
hotel
deliv
synergi
plate
reader
determin
luminesc
assay
biotek
washer
use
aspir
media
dispers
substrat
entireti
screen
took
h
complet
raw
data
ht
assay
subject
statist
analysi
use
softwar
packag
design
analysi
ht
data
part
bioconductor
project
statist
comput
raw
data
normal
use
plate
median
method
next
zscore
transform
appli
center
scale
data
across
experi
replic
given
compound
given
dose
n
dosecompound
combin
mean
summar
zscore
threshold
chosen
identifi
potenti
hit
thereaft
reach
smaller
tractabl
set
hit
valid
experiment
took
advantag
test
compound
four
concentr
specif
use
selforgan
map
analysi
cluster
hit
compound
shape
doserespons
curv
signific
chang
dose
dose
also
analyz
use
linear
model
moder
fstatist
implement
limma
packag
bioconductor
concentrationrespons
curv
compound
visual
inspect
use
scatter
plot
gener
tibco
spotfir
decisionsit
tibco
palo
alto
ca
respect
shape
curv
reproduc
replic
compound
show
errat
concentrationrespons
eg
increas
decreas
increas
isr
activ
increas
concentr
reject
compound
consist
increas
decreas
respons
increas
drug
concentr
good
efficaci
concentr
includ
valid
approach
led
select
compound
valid
includ
compound
highest
zscore
hit
primari
screen
valid
use
isr
activityluciferas
report
assay
broad
rang
compound
concentr
mm
absenc
presenc
ifnb
uml
determin
drug
potenc
defin
halfmaxim
effect
concentr
ec
data
fit
fourparamet
concentrationrespons
curv
describ
previous
use
log
agonist
concentr
versu
respons
variabl
slope
algorithm
graphpad
prism
softwar
la
jolla
ca
bottom
topbottom
hillslop
determin
whether
compound
effect
depend
ifn
product
isr
activityluciferas
report
assay
also
perform
presenc
mous
antihuman
ifnab
receptor
chain
block
mab
clone
millipor
billerica
concentr
mgml
resazurin
alamar
blue
metabol
assay
use
assess
cell
toxic
compound
treatment
experi
cell
treat
compound
equival
concentr
vehicl
dmso
h
medium
replac
fresh
medium
contain
resazurin
dilut
kit
sigmaaldrich
st
loui
mo
h
standard
cultur
condit
fluoresc
result
product
resorufin
measur
use
synergi
plate
reader
well
cell
contain
compound
dmso
alon
well
contain
cell
use
viabil
control
data
normal
calcul
percentag
viabil
express
isg
assess
realtim
quantit
pcr
assay
correspond
mrna
level
experi
cell
first
treat
program
combin
compound
ifnb
h
wash
twice
cold
dulbecco
pb
follow
lysi
cellstocdna
ii
lysi
buffer
life
technolog
treatment
dnase
accord
manufactur
instruct
cell
obtain
g
stark
cleveland
clinic
complement
gener
cell
describ
previous
aliquot
cell
lysat
use
gener
cdna
use
high
capac
revers
transcript
kit
life
technolog
result
cdna
quantifi
use
quantit
oligreen
ssdna
kit
life
technolog
averag
cdna
concentr
ngml
subsequ
pcr
assay
perform
adher
miqe
guidelin
includ
design
assay
isg
normal
gene
ornithin
decarboxylas
antizym
normal
gene
select
valid
cell
sampl
treat
without
ifnb
brief
candid
normal
gene
select
combin
invari
gene
select
previou
microarray
data
prior
largescal
analys
publicli
avail
microarray
data
candid
test
use
realtim
quantit
pcr
assay
comparison
candid
normal
gene
express
variou
ifn
treatment
infect
condit
use
multipl
softwar
packag
led
select
normal
gene
primer
probe
realtim
quantit
pcr
assay
design
use
probefind
design
algorithm
roch
appli
scienc
use
forward
revers
primer
along
upl
probe
roch
appli
scienc
plasmid
contain
transcript
variant
cdna
ref
id
origen
rockvil
md
use
standard
absolut
quantit
copi
number
use
forward
revers
primer
along
upl
probe
plasmid
contain
cdna
clone
id
thermo
open
biosystem
huntsvil
al
use
standard
idt
primetim
predesign
assay
integr
dna
technolog
coralvil
ia
use
cdna
vector
use
well
clone
id
thermo
open
biosystem
data
collect
lightcycl
instrument
roch
appli
scienc
quantif
cycl
valu
calcul
use
second
deriv
maxima
algorithm
implement
lightcycl
softwar
cell
cultur
overnight
treat
compound
ifnb
h
thereaft
cell
wash
inocul
emcv
strain
atcc
manassa
va
h
moi
describ
previous
cell
wash
twice
cultur
medium
contain
fetal
bovin
serum
h
time
cell
supernat
use
determin
viral
titer
base
realtim
quantit
pcr
assay
emcv
rna
forward
primer
revers
primer
probe
ta
plasmid
contain
emcv
protein
use
standard
absolut
quantit
viral
copi
number
addit
cell
viabil
determin
use
cellom
arrayscan
vti
high
content
imag
thermo
scientif
assay
imag
per
well
obtain
object
background
subtract
cell
identifi
nuclei
stain
cell
permeabl
dye
hoechst
propidium
iodid
fluoresc
quantifi
defin
boundari
pixel
around
nuclei
gate
cell
popul
show
higher
stain
sampl
replic
cytotox
calcul
percentag
cell
show
increas
propidium
iodid
stain
base
sampl
least
cell
per
well
